Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
UK: A recent study published in BMJ Medicine found that more caffeine in the blood can reduce the risk of type 2 diabetes and obesity. more...
Read Full NewsThe rheumatology year in review highlights FDA approvals and pivotal data readouts.
Johnson & Johnson plans to initiate a phase 3 study based off the positive data.
Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.
Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.
The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.
Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101
Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression
1.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
2.
PFS in R/R Mantle Cell Lymphoma is Improved by Ibrutinib-Venetoclax.
3.
Nasal therapeutic HPV vaccine could prevent cervical cancer
4.
Can Oligonucleotide Infusions Really Fix Lyme, Cancer, and Other Diseases?
5.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
1.
Exploring the Mystery of Angiokeratomas on Scrotum: Causes, Symptoms and Treatment
2.
The Growing Crisis of Aplastic Anemia: A Call for Action
3.
Neoadjuvant Abraxane Chemotherapy Combined with Neutrophil Cytopharmaceuticals and Radiotherapy
4.
Uncovering Dyscrasia: A Comprehensive Guide to Diagnosis and Treatment
5.
Inside Oncology Trials: From Protocol to Progress in Cancer Research and Care
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
2.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
5.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge